Mutation News and Research

RSS

TSRI study points way to potential therapies for hereditary spastic paraplegia

Scientists at The Scripps Research Institute have discovered that a gene mutation linked to hereditary spastic paraplegia, a disabling neurological disorder, interferes with the normal breakdown of triglyceride fat molecules in the brain. The TSRI researchers found large droplets of triglycerides within the neurons of mice modeling the disease.

30 Sep 2014

Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

A world-first study in today's New England Journal of Medicine heralds the efficacy of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma.

29 Sep 2014

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Survey: Many patients not always well informed about treatment options

More than three quarters of oncology specialists in Europe, South America and Asia believe their patients are not always well enough informed about the treatment options available to them, survey results have revealed at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Myriad Genetics' Tumor BRACAnalysis CDx identifies 44% more candidates for PARP therapy

Myriad Genetics, Inc. today announced that its Tumor BRACAnalysis CDx- companion diagnostic test significantly improved the detection of cancer-causing BRCA1/2 mutations by 44 percent in women with ovarian cancer. Data from this new study were presented at the 2014 European Society for Medical Oncology annual meeting in Madrid, Spain.

29 Sep 2014

Researchers create new Cas9 animal model for in vivo genome editing experiments

Researchers from the Broad Institute and Massachusetts Institute of Technology have created a new mouse model to simplify application of the CRISPR-Cas9 system for in vivo genome editing experiments.

29 Sep 2014

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration, academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies.

29 Sep 2014

Understanding how neurons encode information

Nathan Urban, interim provost and the Dr. Frederick A. Schwertz Distinguished Professor of Life Sciences, and Robert Kass, professor of statistics and machine learning, have received a $930,000 grant from the National Science Foundation to apply biological and statistical neuroscience approaches in order to create a better overall understanding of how neurons encode information.

29 Sep 2014

Fecal occult blood screening increases diagnosis rate of high-risk polyps by 89%

The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk pre-cancerous adenomas (sometimes called polyps) by 89%, researchers have reported at the ESMO 2014 Congress in Madrid.

29 Sep 2014

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.

29 Sep 2014

UCLA research may lead to novel treatment for PH1

Research by UCLA biochemists may lead to a new treatment - or even a cure - for PH1, a rare and potentially deadly genetic kidney disease that afflicts children. Their findings also may provide important insights into treatments for Parkinson's disease, Alzheimer's disease and other degenerative diseases.

27 Sep 2014

Research findings provide clues for design of future HIV vaccine

Scientists at The Scripps Research Institute have described how a single family of antibodies that broadly neutralizes different strains of HIV has evolved remarkably diverse structures to attack a vulnerable site on the virus.

26 Sep 2014

International researchers identify novel causes for severe childhood epilepsies

In the largest collaborative study so far, an international team of researchers, including scientists from VIB and Antwerp University identified novel causes for severe childhood epilepsies.

26 Sep 2014

Two genes that cause pediatric glaucoma increases risk of future stroke up to ten times

Every year in Canada about 50,000 people suffer from a stroke, caused either by the interruption of blood flow or uncontrolled bleeding in the brain. While many environmental risk factors exist, including high blood pressure and smoking, stroke risk is also frequently inherited. Unfortunately, remarkably little is known regarding stroke's genetic basis.

26 Sep 2014

Study findings have potential to advance treatments for small cell lung cell cancer

Two recently published studies by a research team at University Hospitals Case Medical Center Seidman Cancer Center have the potential to advance treatments for small cell lung cell cancer (SCLC). This aggressive form of lung cancer has seen no treatment advances in 30 years and "is a disease in urgent need of new drug therapies," write the study's authors.

26 Sep 2014

Triple-punch of antibodies prevents, wipes out hepatitis C infection in laboratory mice

A triple-punch of antibodies both prevented hepatitis C infection and wiped out the disease after it had established itself in laboratory mice, according to a study led by Princeton University researchers.

26 Sep 2014

Researchers reveal why RB1 gene mutations primarily cause retinoblastomas in children

Retinoblastoma is a childhood retinal tumor usually affecting children one to two years of age. Although rare, it is the most common malignant tumor of the eye in children.

25 Sep 2014

Northwestern scientists develop first animal model for ALS dementia

The first animal model for ALS dementia, a form of ALS that also damages the brain, has been developed by Northwestern Medicine- scientists. The advance will allow researchers to directly see the brains of living mice, under anesthesia, at the microscopic level. This will allow direct monitoring of test drugs to determine if they work.

25 Sep 2014

XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

Patients with advanced lung adenocarcinoma who produce the XAGE1 antibody appear to survive twice as long as those who do not produce it, Japanese study data show.

24 Sep 2014

Mutation News and Research

TSRI study points way to potential therapies for hereditary spastic paraplegia

Combination therapy achieves greater progression-free survival, response rates in melanoma

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Survey: Many patients not always well informed about treatment options

Myriad Genetics' Tumor BRACAnalysis CDx identifies 44% more candidates for PARP therapy

Researchers create new Cas9 animal model for in vivo genome editing experiments

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

Understanding how neurons encode information

Fecal occult blood screening increases diagnosis rate of high-risk polyps by 89%

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

UCLA research may lead to novel treatment for PH1

Research findings provide clues for design of future HIV vaccine

International researchers identify novel causes for severe childhood epilepsies

Two genes that cause pediatric glaucoma increases risk of future stroke up to ten times

Study findings have potential to advance treatments for small cell lung cell cancer

Triple-punch of antibodies prevents, wipes out hepatitis C infection in laboratory mice

Researchers reveal why RB1 gene mutations primarily cause retinoblastomas in children

Northwestern scientists develop first animal model for ALS dementia

XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News